Search

Author/Creator Mehta, N.N.

1. Anti‐inflammatory therapy with tumour necrosis factor inhibitors is associated with reduced risk of major adverse cardiovascular events in psoriasis. (1st May 2018)

Authors:
Wu, J.J.; Joshi, A.A.; Reddy, S.P.; Batech, M.; Egeberg, A.; Ahlehoff, O.; Mehta, N.N.
Journal:
Journal of the European Academy of Dermatology and Venereology
Issue:
Volume 32:Number 8(2018)
Page Start:
1320
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5‐year data from reSURFACE 1 and reSURFACE 2. (25th June 2022)

Authors:
Fernandez, A.P.; Dauden, E.; Gerdes, S.; Lebwohl, M.G.; Menter, M.A.; Leonardi, C.L.; Gooderham, M.; Gebauer, K.; Tada, Y.; Lacour, J.P.; Bianchi, L.; Egeberg, A.; Pau‐Charles, I.; Mendelsohn, A.M.; Rozzo, S.J.; Mehta, N.N.
Journal:
Journal of the European Academy of Dermatology and Venereology
Issue:
Volume 36:Number 10(2022)
Page Start:
1774
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗